http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 07:17:44 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29+at+Buy/27189610.html <p>Ladenburg Thalmann analyst Caroline Palomeque initiates coverage on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) with a Buy rating and a price target of $55.00.</p><p>For an analyst ratings summary and ratings history on Harmony Biosciences Holdings Inc. <a href="http://www.streetinsider.com/rating_history.php?q=HRMY">click here</a>. For more ratings news on Harmony Biosciences Holdings Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=HRMY&amp;type=analyst">click here</a>.</p><p>Shares of Harmony Biosciences Holdings Inc. closed at $37.51 yesterday.</p> http://www.streetinsider.com/New+Coverage/Ladenburg+Thalmann+Starts+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29+at+Buy/27189610.html Thu, 15 Oct 2026 07:17:44 -0400 HRMY http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Harmony+Biosciences+Hold++For%3A+Oct+12/27177411.html si-local-file:///var/storage/secattach/20261013/27177411.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Harmony+Biosciences+Hold++For%3A+Oct+12/27177411.html Tue, 13 Oct 2026 08:00:00 -0400 HRMY http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29/27176685.html <p>H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $55.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).</p><p>The analyst commented: "On October 12, Harmony announced that COO Peter Anastasiou will succeed Jeffrey Dayno as President and CEO on January 1, 2027; CEO Dayno will retire at year-end and remain a non-executive advisor throughout 2027. Following our discussion with both executives, we view the internal handoff and extended overlap as supportive of continuity rather than a strategic reset. Harmony reaffirmed 2026 WAKIX (pitolisant) net revenue guidance of $1.00 billion–$1.04 billion, which compares to our $1.04 billion estimate and the http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29/27176685.html Tue, 13 Oct 2026 06:49:51 -0400 HRMY http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html <p>Truist Securitas's Biotechnology Earnings Preview</p><p>The analyst commented: "Ahead of 3Q26 earnings prints, we provide our latest thoughts on the set-ups and updated sales estimates for our commercial stage biotech companies: ALNY, ARGX, BBIO, BIIB, HRMY, INSM, NBIX, and VRTX. We continue to view catalysts beyond earnings as the primary drivers of performance across our coverage through year-end. The notable exceptions are INSM, BBIO, and NBIX, where we expect 3Q results to drive the greatest near-term share-price volatility.</p><p>For INSM and BBIO, expectations appear tempered heading into the quarter, lowering the bar for a favorable stock reaction. For INSM, prescription trends are http://www.streetinsider.com/Analyst+Comments/Truist+Securitas%27s+Biotechnology+Earnings+Preview%3A+%27INSM%2C+BBIO%2C+NBIX+Most+Levered+to+the+Print%27/27174431.html Mon, 12 Oct 2026 09:04:19 -0400 ALNY ARGX BBIO BIIB HRMY INSM NBIX VRTX http://www.streetinsider.com/Management+Changes/Harmony+Biosciences+names+new+CEO+effective+January+2027/27173779.html <p>Harmony Biosciences Holdings (Nasdaq: HRMY) announced that Peter Anastasiou, currently serving as Senior Executive Vice President and Chief Operating Officer, will become President and Chief Executive Officer effective January 1, 2027.</p> <p>Anastasiou, who previously served three years on Harmony's board of directors, will succeed Jeffrey M. Dayno, M.D., who is retiring after a nine-year tenure at the company, including time as Chief Medical Officer. Dayno will step down from the board on December 31, 2026, and will serve as a non-executive advisor to Harmony throughout 2027.</p> <p>Before joining Harmony, Anastasiou served as CEO of Capsida Biotherapeutics, where he raised more than $165 http://www.streetinsider.com/Management+Changes/Harmony+Biosciences+names+new+CEO+effective+January+2027/27173779.html Mon, 12 Oct 2026 07:00:27 -0400 HRMY http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+Announces+Planned+CEO+Transition+to+Support+Next+Phase+of+Growth/27173744.html <p align="center"><em>The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027.</em></p> <p align="center"><em>Current CEO Jeffrey M. Dayno, M.D., will retire at the end of the year following a nine-year tenure at the Company, including as Chief Medical Officer, and step down as a member of the Board.</em></p> <p align="center"><em>The Company reiterates full-year 2026 WAKIX® net revenue guidance of $1.0 billion to $1.04 billion, remains on track to report data from the multiple ascending dose http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+Announces+Planned+CEO+Transition+to+Support+Next+Phase+of+Growth/27173744.html Mon, 12 Oct 2026 07:00:00 -0400 HRMY http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+Announces+Planned+CEO+Transition+to+Support+Next+Phase+of+Growth/27173744.html <p align="center"><em>The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027.</em></p> <p align="center"><em>Current CEO Jeffrey M. Dayno, M.D., will retire at the end of the year following a nine-year tenure at the Company, including as Chief Medical Officer, and step down as a member of the Board.</em></p> <p align="center"><em>The Company reiterates full-year 2026 WAKIX® net revenue guidance of $1.0 billion to $1.04 billion, remains on track to report data from the multiple ascending dose http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+Announces+Planned+CEO+Transition+to+Support+Next+Phase+of+Growth/27173744.html Mon, 12 Oct 2026 07:00:00 -0400 HRMY http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+Announces+Poster+Presentation+at+the+17th+European+Narcolepsy+Days/27131923.html <p align="left">PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.</p> <p>Poster details are listed below:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: top ; "><strong>Abstract Title</strong>:</td><td style="max-width:90%; width:90%; min-width:90%;;vertical-align: top ; "><em>Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+Announces+Poster+Presentation+at+the+17th+European+Narcolepsy+Days/27131923.html Thu, 01 Oct 2026 08:05:00 -0400 HRMY http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+Announces+Poster+Presentation+at+the+17th+European+Narcolepsy+Days/27131923.html <p align="left">PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.</p> <p>Poster details are listed below:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:10%; width:10%; min-width:10%;;vertical-align: top ; "><strong>Abstract Title</strong>:</td><td style="max-width:90%; width:90%; min-width:90%;;vertical-align: top ; "><em>Phase 3, randomized, double-blind, placebo-controlled studies of HBS-301 for narcolepsy and idiopathic http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+Announces+Poster+Presentation+at+the+17th+European+Narcolepsy+Days/27131923.html Thu, 01 Oct 2026 08:05:00 -0400 HRMY http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Outperform+Rating+on+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29/27098198.html <p>Oppenheimer analyst Andreas Argyrides reiterated an Outperform rating and $70.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)</p><p>The analyst comments "A new patent complaint was filed today against AET adding yet another line of defense around WAKIX and further reinforcing our view that generic entry prior to March 2030 grows increasingly unlikely. The newly asserted US Patent No. 11,945,788 covers methods of manufacturing pitolisant and represents a distinct legal pathway separate from the ongoing ANDA litigation and the recently asserted ‘920 patent. The complaint alleges that AET's Indian manufacturing source utilizes processes covered by the ‘788 patent. This filing http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Outperform+Rating+on+Harmony+Biosciences+Holdings+Inc.+%28HRMY%29/27098198.html Thu, 24 Sep 2026 05:42:40 -0400 HRMY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Harmony+Biosciences+Hold++For%3A+Sep+16++Filed+by%3A+Budur+Kumar/27081089.html si-local-file:///var/storage/secattach/20260918/27081089.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Harmony+Biosciences+Hold++For%3A+Sep+16++Filed+by%3A+Budur+Kumar/27081089.html Fri, 18 Sep 2026 16:48:00 -0400 HRMY http://www.streetinsider.com/SEC+Filings/Form++144++++++++Harmony+Biosciences+Hold+++++++++++++++Filed+by%3A+Budur+Kumar/27080764.html si-local-file:///var/storage/secattach/20260918/27080764.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Harmony+Biosciences+Hold+++++++++++++++Filed+by%3A+Budur+Kumar/27080764.html Fri, 18 Sep 2026 16:20:00 -0400 HRMY http://www.streetinsider.com/SEC+Filings/Form++144++++++++Harmony+Biosciences+Hold+++++++++++++++Filed+by%3A+Budur+Kumar/27076369.html si-local-file:///var/storage/secattach/20260917/27076369.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Harmony+Biosciences+Hold+++++++++++++++Filed+by%3A+Budur+Kumar/27076369.html Thu, 17 Sep 2026 16:35:00 -0400 HRMY http://www.streetinsider.com/SEC+Filings/Form++144++++++++Harmony+Biosciences+Hold+++++++++++++++Filed+by%3A+Budur+Kumar/27070754.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260916/AJ2Z522CZ222SJZZ2Z2U2Z4Z7UQUZJD2ZU82">http://archive.fast-edgar.com/20260916/AJ2Z522CZ222SJZZ2Z2U2Z4Z7UQUZJD2ZU82</a></p> <p> Filed on: September 16, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++144++++++++Harmony+Biosciences+Hold+++++++++++++++Filed+by%3A+Budur+Kumar/27070754.html Wed, 16 Sep 2026 16:34:00 -0400 HRMY http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+Announces+Poster+Presentations+at+the+16th+European+Epilepsy+Congress/27022264.html <p>PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16^th European Epilepsy Congress being held from September 5-9, in Athens, Greece.</p> <p>The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are currently enrolling, and more information can be found at <a href="https://www.globenewswire.com/Tracker?data=fpyMQdkWPXR7eDFUAhqfqoJTP6a1o4c1NjSl_lEZ6QIlSBdU76xV6PEQfHvIC-_L2PxtnhZwON9hHhUKSdaGUw==" rel="nofollow" target="_blank">argustrial.com</a> and <a href="https://www.globenewswire.com/Tracker?data=b4K7ZT1vJmLjXvr1eR5pK1t7mL7lyo9smIyq7Gy3vDQeUfO9BESMxZaHfc7w5qgw8Zh_21B5dXcasTlV2jjbz2InQDSLGmaVTpqR6uLoqZtq7dmgaNOl2RqsEygDK61UcMPLJOoPWb-C4Zxd33M-ow==" rel="nofollow" target="_blank">lighthouselgsstudy.com</a>.</p> <p>Poster presentation details are listed below:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+Announces+Poster+Presentations+at+the+16th+European+Epilepsy+Congress/27022264.html Thu, 03 Sep 2026 08:05:00 -0400 HRMY http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+Announces+Poster+Presentations+at+the+16th+European+Epilepsy+Congress/27022264.html <p>PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16^th European Epilepsy Congress being held from September 5-9, in Athens, Greece.</p> <p>The company is investigating EPX-100 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome in the ongoing ARGUS and LIGHTHOUSE trials, respectively. These trials are currently enrolling, and more information can be found at <a href="https://www.globenewswire.com/Tracker?data=fpyMQdkWPXR7eDFUAhqfqoJTP6a1o4c1NjSl_lEZ6QIlSBdU76xV6PEQfHvIC-_L2PxtnhZwON9hHhUKSdaGUw==" rel="nofollow" target="_blank">argustrial.com</a> and <a href="https://www.globenewswire.com/Tracker?data=b4K7ZT1vJmLjXvr1eR5pK1t7mL7lyo9smIyq7Gy3vDQeUfO9BESMxZaHfc7w5qgw8Zh_21B5dXcasTlV2jjbz2InQDSLGmaVTpqR6uLoqZtq7dmgaNOl2RqsEygDK61UcMPLJOoPWb-C4Zxd33M-ow==" rel="nofollow" target="_blank">lighthouselgsstudy.com</a>.</p> <p>Poster presentation details are listed below:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+Announces+Poster+Presentations+at+the+16th+European+Epilepsy+Congress/27022264.html Thu, 03 Sep 2026 08:05:00 -0400 HRMY http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+to+Participate+in+2026+Cantor+Global+Healthcare+Conference/26985132.html <p>PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.</p> <p>A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at <a href="https://www.globenewswire.com/Tracker?data=XEL3wSf2T8GPco-IORvpBixMENROIuPCa3Fk6IOjn-0A3V2gECNHhJtoCHLKhMu0uSaWX77RneAN38lzZc__mYmIhgnvAQsKIzeFOov5ySppbwD0yVQppgU_JxLdQy7lbz0rIwCoQgknXRI6BPygJvDbCzh8jiW3V0KwmyGc8svBN4bL1rqF1EJVYrAYMSVkoAhUrjKOI9s2LziWfqkk7wZ6EJbq7rW-S2YLSB9tNgIPEyaArmKOaGcYccAgwn1Vvrtqo3s3FQ-bsn3FNzE2S5fVLbZwuyUxkeQBVDWvIA4gkGkSGLGLAqLm4dnu9CE_vNSvrUK2z-nOhCFj_JeTpkPoD_A-c6mhn3Z0CT_EfvwegMFQ1ejaIcqasDmGG9yWOwYJvWDnDBP43T8dRxGX-g==" rel="nofollow" target="_blank">https://ir.harmonybiosciences.com/</a>.</p> <p><strong>About Harmony Biosciences</strong><br />Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. http://www.streetinsider.com/Press+Releases/Harmony+Biosciences+to+Participate+in+2026+Cantor+Global+Healthcare+Conference/26985132.html Thu, 27 Aug 2026 08:05:00 -0400 HRMY http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+to+Participate+in+2026+Cantor+Global+Healthcare+Conference/26985132.html <p>PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.</p> <p>A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at <a href="https://www.globenewswire.com/Tracker?data=XEL3wSf2T8GPco-IORvpBixMENROIuPCa3Fk6IOjn-0A3V2gECNHhJtoCHLKhMu0uSaWX77RneAN38lzZc__mYmIhgnvAQsKIzeFOov5ySppbwD0yVQppgU_JxLdQy7lbz0rIwCoQgknXRI6BPygJvDbCzh8jiW3V0KwmyGc8svBN4bL1rqF1EJVYrAYMSVkoAhUrjKOI9s2LziWfqkk7wZ6EJbq7rW-S2YLSB9tNgIPEyaArmKOaGcYccAgwn1Vvrtqo3s3FQ-bsn3FNzE2S5fVLbZwuyUxkeQBVDWvIA4gkGkSGLGLAqLm4dnu9CE_vNSvrUK2z-nOhCFj_JeTpkPoD_A-c6mhn3Z0CT_EfvwegMFQ1ejaIcqasDmGG9yWOwYJvWDnDBP43T8dRxGX-g==" rel="nofollow" target="_blank">https://ir.harmonybiosciences.com/</a>.</p> <p><strong>About Harmony Biosciences</strong><br />Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. http://www.streetinsider.com/Globe+Newswire/Harmony+Biosciences+to+Participate+in+2026+Cantor+Global+Healthcare+Conference/26985132.html Thu, 27 Aug 2026 08:05:00 -0400 HRMY